FDA limits COVID-19 vaccine access to high-risk individuals, reshaping public health policy amid ongoing debates on vaccine ...

Under the second Trump administration, CMMI has published far more detail about peformance of Enhancing Oncology Model ...

Chronic urticaria patients may have a higher risk of metabolic syndrome, with a pooled prevalence of 25.2% and an odds ratio ...

Many patients later diagnosed with high-grade serous cancer had prior surgical or genetic testing opportunities that could ...

Metabolic syndrome severity is a meaningful marker of chronic kidney disease risk even when patients do not have other major ...

Medical school application and matriculation rates decreased for underrepresented racial and ethnic minorities in medicine ...

Patients with acute respiratory failure who’ve been placed on a mechanical ventilator are less likely to be transferred to high-volume centers if they are uninsured, thus increasing their odds of ...

Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more ...

Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity.

In the final clip, James D. Chalmers, MBChB, PhD, notes that while the FDA approval of brensocatib is a milestone, questions remain on optimal patient selection, long-term benefits, and further ...

Renal denervation modestly lowers blood pressure, with durable long-term benefits, according to Deepak L. Bhatt, MD, MPH, MBA ...

Experts discuss the persistent clinical and systemic challenges in diagnosing and treating atrial fibrillation, emphasizing ...